BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37356928)

  • 1. [Clinical Characteristics and Survival Analysis of Patients with Plasma Cell Leukemia].
    Wang SF; Qin XQ; Guo QH; Wang JY; Ma YP
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):693-698. PubMed ID: 37356928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-based Regimens Improve the Outcome of Patients with Primary or Secondary Plasma Cell Leukemia: A Retrospective Cohort Study.
    Wang H; Zhou H; Zhang Z; Geng C; Chen W
    Turk J Haematol; 2020 May; 37(2):91-97. PubMed ID: 31769277
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and cytogenetic characteristics of primary and secondary plasma cell leukemia under the new IMWG definition criteria: a retrospective study.
    Guan J; Ma J; Chen B
    Hematology; 2023 Dec; 28(1):2254556. PubMed ID: 37732631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The clinical characteristics of patients with primary plasma cell leukemia and the efficacy of novel agents and hematopoietic stem cell transplantation].
    Li WJ; Wang FR; Wen L; Chen Y; Chen H; Huang XJ; Lu J
    Zhonghua Nei Ke Za Zhi; 2020 Oct; 59(10):801-806. PubMed ID: 32987483
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinicopathological and laboratory parameters of plasma cell leukemia among Indian population.
    Dubey H; Goel H; Verma S; Gupta S; Tanwar K; Rahul E; Kapoor G; Vasantharaman J; Ranjan A; Tanwar P; Chopra A
    Am J Blood Res; 2022; 12(6):190-195. PubMed ID: 36742277
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
    Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
    Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival outcomes of patients with primary plasma cell leukemia (pPCL) treated with novel agents.
    Mina R; Joseph NS; Kaufman JL; Gupta VA; Heffner LT; Hofmeister CC; Boise LH; Dhodapkar MV; Gleason C; Nooka AK; Lonial S
    Cancer; 2019 Feb; 125(3):416-423. PubMed ID: 30332496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
    Yu T; Xu Y; An G; Tai YT; Ho M; Li Z; Deng S; Zou D; Yu Z; Hao M; Anderson KC; Qiu L
    Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e652-e659. PubMed ID: 32624447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma cell leukemia: a rare condition.
    Jiménez-Zepeda VH; Domínguez VJ
    Ann Hematol; 2006 Apr; 85(4):263-7. PubMed ID: 16416115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic aberrations and survival in plasma cell leukemia.
    Tiedemann RE; Gonzalez-Paz N; Kyle RA; Santana-Davila R; Price-Troska T; Van Wier SA; Chng WJ; Ketterling RP; Gertz MA; Henderson K; Greipp PR; Dispenzieri A; Lacy MQ; Rajkumar SV; Bergsagel PL; Stewart AK; Fonseca R
    Leukemia; 2008 May; 22(5):1044-52. PubMed ID: 18216867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcomes of patients with plasma cell leukemia in the era of novel therapies and hematopoietic stem cell transplantation strategies: a single-institution experience.
    Lebovic D; Zhang L; Alsina M; Nishihori T; Shain KH; Sullivan D; Ochoa-Bayona JL; Kharfan-Dabaja MA; Baz R
    Clin Lymphoma Myeloma Leuk; 2011 Dec; 11(6):507-11. PubMed ID: 21813352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of first-line treatment with anti-CD38 monoclonal antibody-based regimen for primary plasma cell leukemia].
    Dou XL; Liu RX; Liu Y; Peng N; Wen L; Wu Y; Li Q; Zhong YP; Zhou X; Liao AJ; Jiang HN; Ma XJ; Dong HH; Fan SJ; Zhao YQ; Hu DH; Lu J
    Zhonghua Yi Xue Za Zhi; 2024 Feb; 104(7):499-506. PubMed ID: 38317361
    [No Abstract]   [Full Text] [Related]  

  • 13. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
    Wang H; Li JY; Sun C; Zhou X
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bortezomib, Doxorubicin, Cyclophosphamide, Dexamethasone Induction Followed by Stem Cell Transplantation for Primary Plasma Cell Leukemia: A Prospective Phase II Study of the Intergroupe Francophone du Myélome.
    Royer B; Minvielle S; Diouf M; Roussel M; Karlin L; Hulin C; Arnulf B; Macro M; Cailleres S; Brion A; Brechignac S; Belhadj K; Chretien ML; Wetterwald M; Chaleteix C; Tiab M; Leleu X; Frenzel L; Garderet L; Choquet S; Fuzibet JG; Dauriac C; Forneker LM; Benboubker L; Facon T; Moreau P; Avet-Loiseau H; Marolleau JP
    J Clin Oncol; 2016 Jun; 34(18):2125-32. PubMed ID: 27114594
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic profile of primary plasma cell leukemia in Korea: comparison with plasma cell myeloma.
    Lee Y; Yun J; Jeong D; Ryu S; Kwon SR; Yun H; Kim SM; Park JH; Lee DS
    Leuk Lymphoma; 2022 Feb; 63(2):385-394. PubMed ID: 34592901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
    Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis].
    Jurczyszyn A; Zawirska D; Skotnicki AB
    Przegl Lek; 2011; 68(6):320-5. PubMed ID: 22039670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party.
    D'Arena G; Valentini CG; Pietrantuono G; Guariglia R; Martorelli MC; Mansueto G; Villani O; Onofrillo D; Falcone A; Specchia G; Semenzato G; Di Renzo N; Mastrullo L; Venditti A; Ferrara F; Palumbo A; Pagano L; Musto P
    Ann Oncol; 2012 Jun; 23(6):1499-502. PubMed ID: 22039089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary Plasma Cell Leukemia: Identity Card 2016.
    Musto P; Simeon V; Todoerti K; Neri A
    Curr Treat Options Oncol; 2016 Apr; 17(4):19. PubMed ID: 26995215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prognosis and Genetic Characteristics of Patients with Plasma Cell Leukemia].
    Wu YL; Wang N; Yan YZ; Yuan LJ; Wang LL; Li HH; Li M
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Dec; 28(6):1804-1810. PubMed ID: 33283702
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.